Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Alector has raised $50.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in November 2024.
Alector's investors include AbbVie, Foresite Capital, Perceptive Advisors, Lilly Asia Ventures, Polaris Partners.
Alector is headquartered in San Francisco, United States.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Alector is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alector — Funding & Investors." VCBacked, November 14, 2024, https://www.vcbacked.co/company/alector. Accessed July 21, 2026.
VCBacked. (2024). Alector — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/alector
{{cite web |title=Alector — Funding & Investors |url=https://www.vcbacked.co/company/alector |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated